In vitro and in vivo activities of three oxazolidinones against nonreplicating mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3217-3223

  Zhang, Ming ^a   Sala, Claudia ^a   Dhar, Neeraj ^a   Vocat, Anthony ^a   Sambandamurthy, Vasan K ^b   Sharma, Sreevalli ^b   Marriner, Gwendolyn ^c   Balasubramanian, V ^b   Cole, Stewart T ^a  

^a EPFL   (Switzerland)

^b ASTRAZENECA   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZD 5847; BEDAQUILINE; CHLORAMPHENICOL; CLARITHROMYCIN; FUSIDIC ACID; HYGROMYCIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PHOSPHATE AZD 5847; RIFAMPICIN; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; PNU-100480; POSIZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LATENT TUBERCULOSIS; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TREATMENT DURATION; ANIMAL; ANOXIA; BACTERIAL COUNT; BAGG ALBINO MOUSE; CELL CULTURE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACETAMIDES; ANIMALS; ANOXIA; ANTITUBERCULAR AGENTS; CELLS, CULTURED; COLONY COUNT, MICROBIAL; FEMALE; LATENT TUBERCULOSIS; LINEZOLID; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES;

EID: 84901257996     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02410-14     Document Type: Article

References (28)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland. (http://www.who.int/tb/publications/ global-report/en/).
2. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann. N. Y. Acad. Sci. 1241:48-70. http://dx.doi.org/10.1111/j.1749-6632. 2011.06330.x.
3. Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, Steitz TA, Duffy EM. 2008. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51:3353-3356. http://dx.doi.org/10. 1021/jm800379d.
4. Patel U, Yan YP, Hobbs FW, Jr, Kaczmarczyk J, Slee AM, Pompliano DL, Kurilla MG, Bobkova EV. 2001. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J. Biol. Chem. 276: 37199-37205. http://dx.doi.org/10.1074/jbc.M102966200.
5. Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC. 2008. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob. Agents Chemother. 52:2226-2227. http://dx.doi.org/10.1128/AAC.00414-07.
6. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E, Moreno S. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56:180-185. http://dx.doi.org/10.1093/jac/dki148.
7. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS. 2006. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58:701-704. http://dx.doi.org/10.1093/jac/dkl298.
8. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C, TBNET Study Group. 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34:387-393. http://dx.doi.org/10.1183/09031936.00009509.
9. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319. http://dx.doi.org/10.1128/AAC.01182-08.
10. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. 2011. Biomarkerassisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55:567-574. http://dx.doi.org/10. 1128/AAC.01179-10.
11. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751. http://dx.doi.org/10.1086/655471.
12. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180:371-376. http://dx.doi.org/10.1164/rccm.200904-0611OC.
13. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 7:e30479. http://dx.doi.org/10.1371/journal.pone.0030479.
14. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK. 2014. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother. 58:495-502. http://dx.doi.org/10.1128/AAC.01903- 13.
15. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR. 2011. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592. http://dx.doi.org/10.1128/ AAC.00076-10.
16. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. 2009. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236-3239. http://dx.doi.org/10.1128/AAC.00228-09.
17. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL. 2008. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 178:1180-1185. http://dx.doi.org/10.1164/rccm. 200806-892OC.
18. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon H-S, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee J-K, Lee D, Kim CT, Dartois V, Park S-K, Cho S-N, Barry CE. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
19. Sala C, Dhar N, Hartkoorn RC, Zhang M, Ha YH, Schneider P, Cole ST. 2010. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54:4150-4158. http://dx.doi.org/10. 1128/AAC.00821-10.
20. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56: 5782-5789. http://dx.doi.org/10.1128/AAC.01125-12
21. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH. 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254-1261. http://dx.doi.org/10.1164/rccm.201012-1949OC.
22. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
23. Balasubramanian V, Gaonkar S, Solapure S, Sambandamurthy V, Shandil R, Mahesh K, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Reddy J, Giridhar J, Deshpande A, Bharath S, Kumar N, Balganesh M, Nandi V, Wright I, Melnick D. 2011. AZD5847, an oxazolidinone for the treatment of tuberculosis: preclinical studies, poster F1-1364. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
24. Louie A, Brown D, Files K, Swift M, Fikes S, Drusano G. 2012. Pharmacodynamics of PNU-100480 (U, Sutezolid), a new oxazolidinone, in combination with its active metabolite in the killing of Mycobacterium tuberculosis (Mtb) in an in vitro hollow fiber infection model (HFIM), abstr A-414, p 1265. Abstr 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
25. Gravestock MB, Acton DG, Betts MJ, Dennis M, Hatter G, McGregor A, Swain ML, Wilson RG, Woods L, Wookey A. 2003. New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains. Bioorg. Med. Chem. Lett. 13:4179-4186. http://dx.doi.org/10.1016/j.bmcl.2003.07.033.
26. Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, Feuerriegel S. 2012. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. 56:2743-2745. http://dx.doi.org/10.1128/AAC.06227-11.
27. Sander P, Belova L, Kidan YG, Pfister P, Mankin AS, Bottger EC. 2002. Ribosomal and non-ribosomal resistance to oxazolidinones: speciesspecific idiosyncrasy of ribosomal alterations. Mol. Microbiol. 46:1295-1304. http://dx.doi.org/10.1046/j.1365-2958.2002.03242.x.
28. Hillemann D, Rusch-Gerdes S, Richter E. 2008. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother. 52:800-801. http://dx.doi.org/10.1128/AAC.01189-07.